FATE supply chain intelligence for Fate Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ALLO g… |
| ALLO | Allogene Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| BMY | Bristol-Myers Squibb Company | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay o… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial cond… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: Reciprocal relationship from CGEM g… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC g… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| IPSC | Century Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legi… |
| LEGN | Legend Biotech Corporation | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial cond… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from FATE graph: ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or d… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legi… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ARTV g… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitute… |
| BMY | Bristol-Myers Squibb Company | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC g… |
| IPSC | Century Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: rt that a claim including items or … |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| LEGN | Legend Biotech Corporation | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: Reciprocal relationship from LEGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: rt that a claim including items or … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitu… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| FATE-DEBT-9428 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2013-12-31. |
| FATE-DEBT | Debt stack $76.8M | 90% | Market cache reports total debt of $76.8M. |
| FATE-DEBT-9427 | Warrants outstanding: 230000 | 90% | xbrl warrant detail from xbrl 2017-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| FATE-OWNER-REDMILE-GROUP-LLC | Redmile Group, LLC | 90% | 13F overlay lists Redmile Group, LLC as top holder; 155 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IMTX | Immatics N.V. | 100.00 | 2 | |
| RNAC | Cartesian Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 50.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 |